A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 compared with placebo in subjects with type 2 diabetes
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 18 Dec 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
- 01 Dec 2008 Results published in Diabetes Care.
- 11 Sep 2008 Results were published in the proceedings of the 44th Annual Meeting of the European Association for the Study of Diabetes